胰腺癌患者血清相关蛋白质差异表达的研究  

Differential expression of serum proteins of pancreatic cancer patients

作　　者：李兴华[1] 方德宁[1] 沈奕[1] 曾钗明[1] 邓淑娟[1] 

机构地区：[1]上海市第八人民医院消化内科,上海200235

出　　处：《中华胰腺病杂志》2010年第4期245-247,共3页Chinese Journal of Pancreatology

基　　金：国家自然科学基金（30370646）;上海市自然科学基金（09ZR1423800）

摘　　要：目的利用肿瘤血清蛋白质组分析方法（serologic proteome analysis，SERPA）对胰腺癌患者血清和正常人血清进行蛋白质组的分析，寻找胰腺癌特异的肿瘤标记物。方法利用HPLC柱去除血清中的白蛋白，通过双向电泳分离蛋白质，经图像采集与分析，切取胰腺癌患者血清和正常人血清的差异蛋白质点，进行质谱分析鉴定。结果共获得4个差异蛋白质。正常人血清含量高而胰腺癌患者血清含量低的蛋白质为胍裂解环化酶激活蛋白2（guanylate cyclase-activating protein 2）。胰腺癌患者血清含量高而正常人血清含量低的蛋白质3个，分别为结合珠蛋白2α（haptoglobin 2 alpha）、转甲状腺素蛋白（transthyretin）及KIAA1018蛋白。结论KIAA1018有望成为胰腺癌筛选和早期诊断的肿瘤标记物。Objective Serologic proteome analysis method （SERPA） was used to compare the different of the serum proteins between normal and pancreatic cancer patients＇ serum, and to find a new specific pancreatic cancer marker. Methods HPLC was used to eliminate albumin from the serum, two-dimensional electrophoresis was used to separate the proteins. After imaging collection and analysis, the different proteins between pancreatic cancer and normal subjects were cut for mass spectrometry. Results Four discrepancy proteins were obtained. Guanylate cyclase-activating protein 2 was highly expressed in normal serum but not pancreatic cancer. Hp2-alpha, transthyretin and KIAA1018 protein were highly expressed in cancer patients＇ serum but not normal people. Conclusions KIAA1018 may become a promising tumor marker for screening and early diagnosis of pancreatic cancer.

关 键 词：胰腺肿瘤 蛋白质组学 血清蛋白质类 肿瘤标记 生物学 

分 类 号：R735.9[医药卫生—肿瘤]